1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

FDA lifts partial hold on OncoMed's ipafricept

 
• By Donna Young

For the second time in the past week, the FDA has lifted a partial hold on the Phase I studies of one of OncoMed Pharmaceuticals' drugs, this time ipafricept (FZD8-Fc, OMP-54F28), clearing the way for it to move forward.

For the second time in the past week, the FDA has lifted a partial hold on the Phase I studies of one of OncoMed Pharmaceuticals' drugs, this time ipafricept (FZD8-Fc, OMP-54F28), clearing the way for it to move forward.

Just last week, the FDA lifted the partial hold on Phase I trials of vantictumab (anti-Fzd7, OMP-18R5), a first-in-class antibody,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Merck & Co.’s Enlicitide Poised To Be First Oral PCSK9 Inhibitor To Market

 
• By Jessica Merrill

The company announced positive data from two Phase III trials testing the cholesterol-lowering medicine.

Sanofi Cements RSV Dominance As Merck & Co. Rival Awaits FDA D-Day

 
• By Kevin Grogan

The French company will start shipping its blockbuster shortly to meet expected strong demand in the 2025–26 RSV season.

Otsuka’s IgAN Data Top Some Vera Results, But To What End?

 
• By Joseph Haas

Otsuka bested Vera on Phase III immunoglobulin A nephropathy data for proteinuria, but analysts wonder if the difference is especially meaningful.